clinical trial · NCT04764188
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
Hoffmann-La Roche·—·active not recruiting·n = 800
NSCLCAlectinib
brief summary
This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice.
started
May 10, 2021
primary completion
May 10, 2027
completion
May 10, 2027
last updated
Apr 13, 2026
official title
A Multicenter Non-Interventional Cohort Study to Evaluate the Real-World Clinical Management and Outcomes of Patients Diagnosed With ALK-Positive Advanced NSCLC Treated With Alectinib (ReAlec)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol